核心医疗董事长曾让80后弟弟余顺理代持股，未认定为一致行动人遭问询

Core Viewpoint - Shenzhen Core Medical Technology Co., Ltd. is preparing for an IPO on the Sci-Tech Innovation Board, focusing on innovative medical devices in the artificial heart sector to address the urgent clinical needs of over 10 million heart failure patients in China [2]. Company Overview - Core Medical is a national high-tech enterprise specializing in the research, development, production, and sales of implantable and interventional artificial heart products [2]. - The company is controlled by Yu Shunzhou, who holds 21.79% of the shares directly and an additional 0.09% indirectly through Shenzhen Xinfuh [2]. Shareholding Structure - Yu Shunzhou controls a total of 29.14% of the voting rights in the company, including shares held through a partnership [2]. - Yu Shunzhou's brother, Yu Shunli, was initially registered to hold shares on behalf of Yu Shunzhou but has not made the required capital contributions [2][4]. Capital Contributions - The registered capital of Core Medical was set at 10 million yuan, with all contributions from Yu Shunzhou made in 2019 totaling 492 million yuan [6]. - The contributions were made in cash from personal funds, and the total amount of 1,000 million yuan was fully paid [6]. Relationship Between Shareholders - Yu Shunzhou and Yu Shunli are considered acting in concert due to their close familial relationship, as defined by regulations [6]. - Yu Shunli has committed to lock up his indirectly held shares in accordance with the same requirements as the actual controller, Yu Shunzhou [6]. Management Background - Yu Shunli has held various financial management positions in different companies and has been involved with Core Medical since 2019 [7]. - Yu Shunzhou has an extensive academic background in mechanical engineering and has held several senior engineering roles before becoming the chairman and general manager of Core Medical [8][9].